Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Development of a nanotechnology-based innovative assay for the diagnosis of allergy to Betalactams

Project description

A nanotechnology-based allergy test

Nearly 1 in 10 individuals develop an allergy to betalactams, the most common class of antibiotics. The current method of diagnosing betalactam allergy is the conventional skin test which, however, may have adverse effects. The scope of the EU-funded ASSERT project is to advance the basophil activation test (BAT) as a routine diagnostic method for betalactam allergy. BAT measures activation of basophils that mediate allergic reactions by releasing histamine following stimulation with allergen. Researchers will employ nanotechnology to improve the precision and reproducibility of the BAT assay and validate it for routine clinical use.

Objective

Betalactams (BL) are the most widely used antibiotics and the first-choice drugs to control several bacterial infections, however, they can lead to serious allergic reactions in up to 10% of the general population. The current diagnosis of allergy to BL includes skin test and/or drug provocation tests, which are invasive and carry a risk of anaphylaxis requiring hospitalisation. Basophil activation test (BAT) is one of the best options for diagnosis of allergy because it is free of risk and at a reduced cost for health care. The ASSERT project will bring a nanotechnology-based BAT assay specific for allergy to BL with higher sensitivity and specificity, which are the main weakness of the current assays. Of importance, the number and conformation of displayed antigens at the nanoparticle surface will be controlled to assure standardisation and increase precision and reproducibility of the assay. In addition, a complete validation plan is envisaged to fit the standards for clinical diagnostics. The two factors for the success of the project are, one one hand, the solid experience of the host lab in immunology, specially allergy and nanoparticle technology and, on the other hand, the expertise of the candidate in immunology, molecular biology and test validation design for clinical diagnostics. Moreover, the the two way of transfer of knowledge is assured, which will help the candidate to restart her research career in the European Union. Finally, the expected results of the project will contribute to enlarge the basic knowledge about allergen-specific activation of basophils, and will give rise to an optimised BL-BAT assay with the required clinical and analytical validation to be used in diagnostics.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-MSCA-IF-2020

See all projects funded under this call

Coordinator

FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 259 398,72
Address
CALLE SEVERO OCHOA 35, PARQUE TECNOLOGICO DE ANDALUCIA
29590 MALAGA
Spain

See on map

Region
Sur Andalucía Málaga
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 259 398,72
My booklet 0 0